HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

KR-32568

Cardioprotective agent; structure in first source

Also Known As:

(5-(2-methyl-5-fluorophenyl)furan-2-ylcarbonyl)guanidine

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amidines: 14
  - Guanidines: 29
    - KR-32568: 1

Experts

1.	Chung, Hun-Jong: 1 article (12/2005)
2.	Jung, In-Sang: 1 article (12/2005)
3.	Kwon, Suk-Hyung: 1 article (12/2005)
4.	Park, Jung-Woo: 1 article (12/2005)
5.	Roh, Hui-Yul: 1 article (12/2005)
6.	Shin, Hwa-Sup: 1 article (12/2005)
7.	Yi, Kyu-Yang: 1 article (12/2005)
8.	Yoo, Sung-Eun: 1 article (12/2005)
9.	Yun, Yeo-Pyo: 1 article (12/2005)

Related Diseases

1.	Ventricular Tachycardia 12/01/2005 - "KR-32568 at the same doses also significantly reduced the total number of ventricular premature beats during ischemia/reperfusion from 530 (control) to 266 and 115 beats, ventricular tachycardia (VT) incidence from 51 (control) to 21 and 8, VT duration from 238 s (control) to 63 and 33 s, ventricular fibrillation (VF) incidence from 17 (control) to 8 and 0, and VF duration from 85 s to 18 and 1 s. "
2.	Ventricular Fibrillation 12/01/2005 - "KR-32568 at the same doses also significantly reduced the total number of ventricular premature beats during ischemia/reperfusion from 530 (control) to 266 and 115 beats, ventricular tachycardia (VT) incidence from 51 (control) to 21 and 8, VT duration from 238 s (control) to 63 and 33 s, ventricular fibrillation (VF) incidence from 17 (control) to 8 and 0, and VF duration from 85 s to 18 and 1 s. "
3.	Ischemia 12/01/2005 - "In our anesthetized rat model, KR-32568 reduced infarct size from 67 (control) to 43 and 24% at 0.1 and 1.0 mg/kg (i.v. bolus, given 10 min before ischemia), respectively. " 12/01/2005 - "KR-32568 at the same doses also significantly reduced the total number of ventricular premature beats during ischemia/reperfusion from 530 (control) to 266 and 115 beats, ventricular tachycardia (VT) incidence from 51 (control) to 21 and 8, VT duration from 238 s (control) to 63 and 33 s, ventricular fibrillation (VF) incidence from 17 (control) to 8 and 0, and VF duration from 85 s to 18 and 1 s. " 12/01/2005 - "The effects of a novel sodium/hydrogen exchanger-1 (NHE-1) inhibitor, KR-32568, were studied in an anesthetized rat model of 30 min ischemia/2.5 h reperfusion heart injury. "
4.	Infarction (Infarctions) 12/01/2005 - "In our anesthetized rat model, KR-32568 reduced infarct size from 67 (control) to 43 and 24% at 0.1 and 1.0 mg/kg (i.v. bolus, given 10 min before ischemia), respectively. "
5.	Heart Injuries 12/01/2005 - "The effects of a novel sodium/hydrogen exchanger-1 (NHE-1) inhibitor, KR-32568, were studied in an anesthetized rat model of 30 min ischemia/2.5 h reperfusion heart injury. "

Related Drugs and Biologics

1.	Sodium
2.	Hydrogen